Project/Area Number |
15K09810
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Psychiatric science
|
Research Institution | Kibi International University (2017) Kochi University (2015-2016) |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
淵上 学 広島大学, 医歯薬保健学研究科(医), 助教 (40403571)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | Bipolar disorder / GSK3beta / BDNF / Lithium / CNV / Biomarker / 双極性障害 / Copy Number Variation / Bipolar Disorder / リチウム / Copy Number Variant / 治療薬反応性 |
Outline of Final Research Achievements |
Although it is known that lithium (Li) is effective in the treatment of bipolar disorders (BDs), a certain patient with BDs poorly responds to Li. It is hypothesized that structural genomic variations in the GSK 3 beta or BDNF gene may change the therapeutic efficacy of Li. One type of structural genomic variations is a copy number variation (CNV). So, we examined the rates of CNVs in GSK 3 beta and BDNF gene based on the Databases of Genomic Variations (DGV) in patients with BDs by quantitative real-time PCR. The therapeutic response to Li was evaluated by Alda Scale. In the BDNF gene, while 5 BD patients were found to have 3 copies of exon IV region within nsv95132, there was no healthy subject having an amplified exon IV region. There was no significant difference in Alda Scale A between BD patients with 3 copies and 2 copies.These findings suggest that CNV within exon IV of the BDNF gene may not be involved in the therapeutic response to Li in patients with BD.
|